Serologic evolution of neurocysticercosis patients after antiparasitic therapy

H. H. Garcia, R. H. Gilman, M. Catacora, M. Verastegui, A. E. Gonzalez, V. C.W. Tsang, M. Martinez, J. Altamirano, L. Trelles, J. M. Cuba, M. Alvarado, G. Alban, H. Estrada, N. Rios-Saavedra, M. Soto, M. P. Torres, J. Boero, C. Gavidia, E. Barron

Research output: Contribution to journalArticlepeer-review

78 Scopus citations


Neurocysticercosis is the main cause of acquired epilepsy in developing countries and is an emerging disease in the United States. Introduction of the immunoblot assay provided a new tool for the diagnosis and monitoring of neurocysticercosis. This study analyzed the relationship between clinical characteristics of cerebral infection (number and type of lesions) plus the baseline response on immunoblot and the changes observed after therapy. Reaction to all 7 diagnostic bands was associated with severe infection (more lesions). Seventeen patients (35%) had no active lesions on computed tomography (CT) 3 months after therapy and were considered cured. Although most cured patients remained seropositive after 1 year, 3 became seronegative before 9 months. In these 3 cases, the lesions had resolved on CT at 3 months. Persistent seropositivity does not necessarily indicate active infection. Serologic follow-up will be clinically helpful only in rare cases in which early antibody disappearance occurs.

Original languageEnglish
Pages (from-to)486-489
Number of pages4
JournalJournal of Infectious Diseases
Issue number2
StatePublished - 1997
Externally publishedYes

Bibliographical note

Funding Information:
Financial support: Institut Malarde and UNDP/World BanklWHO Special Programme for Research and Training in Tropical Diseases, Task Force on Operational Research on Filariasis.

Funding Information:
Received 8 July 1996; revised 23 September 1996. Informed consent was obtained from all patients, and the study was approved by the ethical review boards of the Universidad Peruana Cayetano Heredia and Johns Hopkins University. Financial support: NIH (AI-35894) and SmithKline Beecham Pharmaceuticals (London). Correspondence: Dr. R. H. Gilman, Dept. of International Health, School of Hygiene and Public Health, Johns Hopkins University, 615 N. Wolfe St., Baltimore, MD 21205. Reprints: Dr. H. H. Garcia, Dept. de Microbiologia, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, Lima 31, Peru. * Members are listed after the text.


Dive into the research topics of 'Serologic evolution of neurocysticercosis patients after antiparasitic therapy'. Together they form a unique fingerprint.

Cite this